Cardiff Lexington Corp
Cardiff Lexington is a healthcare holding company that acquires and builds middle-market niche healthcare businesses, with a focus on orthopedics, spine care and pain management. Its healthcare operations are conducted through Nova Ortho and Spine, which runs eleven facilities across Florida and Georgia. The facilities provide care primarily to traumatic injury victims, including primary care evaluations, interventional pain management, specialty consultations and diagnostic and surgical services such as joint replacement, fracture care and spinal surgery. Patients are primarily referred by personal injury attorneys, insurance carriers, physical therapy providers and chiropractors. Cardiff Lexington’s healthcare services are paid for primarily through bodily injury, general liability and personal injury protection policies. The company also owns Edge View Properties, a real estate subsidiary with land in Lemhi County, Idaho. Cardiff Lexington is headquartered in Lexington, Kentucky.
No SEC Form 4 filings for $CDIX in the last 30 days.
See all $CDIX insider activity →Cardiff Lexington reported 3Q 2026 revenue of $1.91M, down 37.5% YoY, and a net loss of $3.5M, widened from $1.41M. EPS was ($0.22). Declines were attributed to fewer healthcare procedures and lower settlement rates. Gross margin fell to 54.22% from 62.43%.
Cardiff Lexington Corp (CDIX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CARDIFF LEXINGTON CORPORATION ANNOUNCES LETTER OF INTENT FOR PROPOSED ACQUISITION OF LEADING MUSCULOSKELETAL HEALTHCARE PLATFORM Proposed Combination Would Significantly Expand Cardiff Lexington’s Musculoskeletal and Ancillary Healthcare Operations LEXINGTON, KY. — S
Cardiff Lexington Corporation (OTCQX:CDIX) filed its Form 10-Q for the quarter ended June 30, 2026. The company reported Q2 2026 revenue of $2.16M versus $2.79M in 2025, and a net loss of $2.48M. For six months, revenue fell to $4.38M and net loss was $5.57M. It cited working capital constraints and plans to evaluate debt restructuring and equity infusions.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CDIX (Cardiff Lexington Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent CDIX coverage spans earnings and corporate actions.
Earnings miss with lower revenue and higher loss likely pressures the stock.
The proposed acquisition could significantly expand CDIX's operations and drive share price higher.
The filing and disclosed losses highlight ongoing liquidity and high-cost capital needs, increasing near-term financing and execution risk.
The filing discloses a potential equity issuance program (fixed purchase notices) tied to a minimum $0.20 trading price, which can pressure dilution and liquidity expectations.
AlphAI scores every news story that mentions CDIX with an AI model for sentiment and relevance, and aggregates insider trades from Cardiff Lexington Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cardiff Lexington reported 3Q 2026 revenue of $1.91M, down 37.5% YoY, and a net loss of $3.5M, widened from $1.41M. EPS was ($0.22). Declines were attributed to fewer healthcare procedures and lower settlement rates. Gross margin fell to 54.22% from 62.43%.
Cardiff Lexington Corp (CDIX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CARDIFF LEXINGTON CORPORATION ANNOUNCES LETTER OF INTENT FOR PROPOSED ACQUISITION OF LEADING MUSCULOSKELETAL HEALTHCARE PLATFORM Proposed Combination Would Significantly Expand Cardiff Lexington’s Musculoskeletal and Ancillary Healthcare Operations LEXINGTON, KY. — S
Cardiff Lexington Corporation (OTCQX:CDIX) filed its Form 10-Q for the quarter ended June 30, 2026. The company reported Q2 2026 revenue of $2.16M versus $2.79M in 2025, and a net loss of $2.48M. For six months, revenue fell to $4.38M and net loss was $5.57M. It cited working capital constraints and plans to evaluate debt restructuring and equity infusions.
Cardiff Lexington Corp (CDIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 cardiff_ex1001.htm COMMON STOCK PURCHASE AGREEMENT, DATED JUNE 5, 2026 Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of June 5, 2026 (this “ Agreement ”), by and among Leonite Fund I, LP (the “ Investor ”),
